1. Домникова Н.П., Долгих Т.Ю. Распространенность миелофиброза при хроническом миелолейкозе, множественной миеломе и хроническом лимфолейкозе в различные фазы заболеваний // Сиб. науч. мед. журн. 2016. (5). 53–57.
2. Программное лечение заболеваний системы крови: Сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови / ред. В.Г. Савченко. М.: Практика, 2012. 1056 с.
3. Ругаль В.И., Бессмельцев С.С., Семенова Н.Ю. Особенности нишеобразующих структур и стромы костного мозга больных хроническим лимфоцитарным лейкозом // Medline.Ru. 2013. 14. (2). 347–361.
4. Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F., Thomas M., Tchernia G., Jacquillat C., Boivin P., Lesty C., Duault M.T., Monconduit M., Belabbes S., Gremy F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis // Cancer. 1981. 48. (1). 198–206.
5. Buesche G., Georgii A., Duensing A., Schmeil А., Schlue J., Kreipe H. Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia // Hum. Pathol. 2003. 34. (4). 391–401.
6. Buesche G., Hehlmann R., Hecker H., Heimpel H., Heinze B., Schmeil A., Pfirrmann M., Gomez G., Tobler A., Herrmann H., Kappler M., Hasford J., Buhr T., Kreipe H.H., Georgii A. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia – prospective long-term results from a randomized-controlled trial // Leukemia. 2003. 17. 2444–2453.
7. Burkhardt R., Bartl R., Jager K., Frisch B., Kettner G, Mahl G., Sund M. Working classification of chronic myeloproliferative disorders based on histological, haematological and clinical findings // J. Clin. Pathol. 1986. 39. 237–252.
8. Clough V., Geary G.C., Hashmi K. Myelofibrosis in chronic granulocytic leukemia // Br. J. Haematol. 1979. 42. 515–526.
9. Crawford S.E., Stellmach V., Murphy-Ullrich J.E., Ribeiro S.M.F., Lawler J., Hynes R.O., Boivin J.P., Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo // Cell. 1998. 93. 1159.
10. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Döhner H., Hillmen P., Keating M.J., Montserrat E., Rai K.R., Kipps T.J. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines // Blood. 2008. 111. (12). 5446–5456.
11. Kantarjian H.M., Bueso-Ramos C.E., Talpaz M., O’Brien S., Giles F., Faderl S., Wierda W., Beth Rios M., Shan J., Cortes J. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy // Cancer. 2005. 104. (4). 777–780.
12. Kimura A., Hyodo H., Nakata Y., Kuramoto A. Chronic lymphocytic leukemia associated with bone marrow fibrosis: Possible role of interleukin 1α in the pathogenesis // Am. J. Hematol. 1993. 43. 47–50.
13. Lazzarino M., Morra E., Castello A., Inverardi D., Coci A., Pagnucco G., Magrini U., Zei G., Bernasconi C. Myelofibrosis in chronic granulocytic leukemia: clinicopathological correlation and prognostic significance // Br. J. Haematol. 1986. 64. 227–240.
14. Rankin E.B., Narla A., Park J.K., Lin S., Sakamoto K.M. Biology of the bone marrow microenvironment and myelodysplastic syndromes // Mol. Genet. Metab. 2015. Vol. 116 (1-2). P. 24–28.
15. Tadmor T., Shvidel L., Aviv A., Ruchlemer R., Bairey O., Yuklea M., Herishanu Ya., Braester A., Levene N., Vernea F., Ben-Ezra J., Bejar J., Polliack A. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications // Cancer. 2013. 119. (10). 1853–1859.
16. Thiele J., Kvasnicka H.M. Myelofibrosis – What′s in a Name? // Pathobiology. 2007. 74. (2). 89–96.
17. Thiele J., Kvasnicka H.M., Facchetti F., Franco V., van der Walt J., Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity // Haematologica. 2005. 90. 1128–1132.
18. Thiele J., Kvasnicka H.M., Titius B.R., Parpert U., Nebel R., Zankovich R., Dienemann D., Stein H., Diehl V., Fischer R. Histological features of prognostic significance in CML: An immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow // Ann. Hematol. 1993. 66. 291–302.
19. Weistner A., Rosenwald A., Barry T.S. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile // Blood. 2003. 101. 4944–4951.